In a report released yesterday, Kennen MacKay from RBC Capital maintained a Buy rating on Clovis Oncology (CLVS), with a price target of $17.00. The company’s shares closed last Monday at $9.92.
According to TipRanks.com, MacKay is a 5-star analyst with an average return of 13.5% and a 55.7% success rate. MacKay covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, BioMarin Pharmaceutical, and Five Prime Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Clovis Oncology with a $18.00 average price target.
See today’s analyst top recommended stocks >>
Based on Clovis Oncology’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $99.5 million. In comparison, last year the company had a GAAP net loss of $99.26 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Clovis Oncology, Inc. is a commercial stage biotechnology company, which engages in the acquisition, development, and commercialization of cancer treatments in the United States, Europe, and other markets. Its product development programs target specific subsets of cancer, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from its use. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
